GT201100321A - "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico" - Google Patents

"acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"

Info

Publication number
GT201100321A
GT201100321A GT201100321A GT201100321A GT201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A GT 201100321 A GT201100321 A GT 201100321A
Authority
GT
Guatemala
Prior art keywords
methyl
trifluorometil
benzazepin
tetrazol
trans
Prior art date
Application number
GT201100321A
Other languages
English (en)
Spanish (es)
Inventor
Scott Alan Frank
Xinchao Chen
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201100321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201100321A publication Critical patent/GT201100321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GT201100321A 2009-06-30 2011-12-13 "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico" GT201100321A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30

Publications (1)

Publication Number Publication Date
GT201100321A true GT201100321A (es) 2012-11-15

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201100321A GT201100321A (es) 2009-06-30 2011-12-13 "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"

Country Status (37)

Country Link
US (2) US8299060B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
BR112014000333A2 (pt) * 2011-07-08 2017-02-07 Novartis Ag método de tratamento de aterosclerose em sujeitos com triglicerídeo alto
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
DK2943474T3 (en) 2013-01-31 2017-08-21 Chong Kun Dang Pharmaceutical Corp BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXE DERIVATE COMPOUNDS AS CETP INHIBITORS
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
CN114381512A (zh) 2014-07-30 2022-04-22 豪夫迈·罗氏有限公司 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
KR100639745B1 (ko) * 2001-04-30 2006-10-30 화이자 프로덕츠 인크. Ｃｅｔｐ 억제제 제조 방법
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
WO2004078730A2 (en) * 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
EP2098512A1 (en) * 2003-10-08 2009-09-09 Eli Lilly & Company Compounds and methods for treating dyslipidemia
US20070208003A1 (en) 2004-03-26 2007-09-06 Bell Michael G Compounds and methods for treating dyslipidemia
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
US20100331309A1 (en) 2010-12-30
CO6480934A2 (es) 2012-07-16
NZ596820A (en) 2013-07-26
EA020600B1 (ru) 2014-12-30
MA33385B1 (fr) 2012-06-01
AU2010266537B2 (en) 2013-04-18
SI2448933T1 (sl) 2013-11-29
TN2011000638A1 (en) 2013-05-24
EP2448933A1 (en) 2012-05-09
UA109409C2 (ru) 2015-08-25
US20120058990A1 (en) 2012-03-08
CN102639528B (zh) 2014-07-16
EA201270099A1 (ru) 2012-05-30
US8329688B2 (en) 2012-12-11
DOP2011000405A (es) 2012-01-15
KR20120027426A (ko) 2012-03-21
JP5689875B2 (ja) 2015-03-25
PT2448933E (pt) 2013-10-29
US8299060B2 (en) 2012-10-30
IL216655A (en) 2015-02-26
AR077208A1 (es) 2011-08-10
SG177413A1 (en) 2012-02-28
CR20110669A (es) 2012-03-16
AU2010266537A1 (en) 2012-02-02
BRPI1011931A2 (pt) 2016-04-19
PL2448933T3 (pl) 2014-01-31
CL2011003263A1 (es) 2012-07-27
TWI450896B (zh) 2014-09-01
JP2012532106A (ja) 2012-12-13
ECSP11011551A (es) 2012-01-31
JO2867B1 (en) 2015-03-15
IL216655A0 (en) 2012-02-29
MX2011014024A (es) 2012-04-20
PE20120538A1 (es) 2012-05-09
DK2448933T3 (da) 2013-10-07
CN102639528A (zh) 2012-08-15
HRP20130950T1 (hr) 2013-11-22
ZA201108707B (en) 2013-05-29
KR101404893B1 (ko) 2014-06-20
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
EP2448933B1 (en) 2013-08-28
ES2435293T3 (es) 2013-12-18
MY157121A (en) 2016-05-13
WO2011002696A1 (en) 2011-01-06
TW201113275A (en) 2011-04-16
CA2764425A1 (en) 2011-01-06
CA2764425C (en) 2015-01-06

Similar Documents

Publication Publication Date Title
GT201100321A (es) "acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil](2-metil-2h-tetrazol- -5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il] metil] -ciclohexan carboxilico"
BRPI0906323A2 (pt) "artigo absorvente descartável do vestuário"
EP2506817A4 (en) Disposable wearing article
BR112012015790A2 (pt) 'artigo do vestuário'
IN2012DN00692A (enExample)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
EP2475675A4 (en) MODULATION OF THE EXPRESSION OF HUNTINGTIN
BR112012020349A2 (pt) "artigo do vestúario descartavel"
ME02979B (me) Kompozicije hemoglobina
BRPI0820515A2 (pt) "artigo do vestuário"
FR2962650B1 (fr) Composition d'immunoglobulines humaines concentrees
FR2933617B1 (fr) Compositions visant a favoriser le developpement et la croissance d'une microflore vaginale benefique
BRPI0916170A2 (pt) "artigo absorvente com característica de alívio de cintura"
BR112012016492A2 (pt) "artigo do vestuário descartavel"
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
IN2012DN00539A (enExample)
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
BRPI1008858A2 (pt) "uso de análogos de ácido heteroaromáticos contendo enxofre como bactericidas"
IT1395539B1 (it) Piede d'appoggio
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
HU0700024D0 (en) Use of enhancers in biglycan activuty in the preparation of pharmaceutical compositions having utility in cardiac diseases
EP2688957A4 (en) POLYMERIC COMPOSITIONS BASED ON BIOLOGICAL BASIS
EP2271365A4 (en) REGULATION OF FATTY ACID TRANSPORTERS
NZ596158A (en) Thioxanthene derivatives for the treatment of infectious diseases
CR20130005A (es) Agentes terapéuticos 976